Logo image
Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach
期刊文章   開放取用(OA)

Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach

陳信宏, Chen-Hsiang Sang, Chang-Wei Chou, Yi-Ting Lin, 張守一信程 邱
Pharmaceutics, 卷.878
29/06/2024

摘要

anti-inflammation;dexamethasone palmitate;nebulization;pneumonia;solid lipid nanoparticles;alveolar macrophages
<p>Pneumonia stands as the leading infectious cause of childhood mortality annually, under-<br role="presentation" />scoring its significant impact on pediatric health. Although dexamethasone (DXMS) is effective for<br role="presentation" />treating pulmonary inflammation, its therapeutic potential is compromised by systemic side effects<br role="presentation" />and suboptimal carrier systems. To address this issue, the current study introduces solid lipid na-<br role="presentation" />noparticles encapsulating hydrophobic dexamethasone palmitate (DXMS-Pal-SLNs) as an anti-in-<br role="presentation" />flammatory nanoplatform to treat pneumonia. The specialized nanoparticle formulation is charac-<br role="presentation" />terized by high drug loading efficiency, low drug leakage and excellent colloidal stability in partic-<br role="presentation" />ular during nebulization and is proficiently designed to target alveolar macrophages in deep lung<br role="presentation" />regions via local delivery with the nebulization administration. In vitro analyses revealed substan-<br role="presentation" />tial reductions in the secretions of tumor necrosis factor-&alpha; and interleukin-6 from alveolar macro-<br role="presentation" />phages, highlighting the potential efficacy of DXMS-Pal-SLNs in alleviating pneumonia-related in-<br role="presentation" />flammation. Similarly, in vivo experiments showed a significant reduction in the levels of these cy-<br role="presentation" />tokines in the lungs of mice experiencing lipopolysaccharide-induced pulmonary inflammation af-<br role="presentation" />ter the administration of DXMS-Pal-SLNs via nebulization. Furthermore, the study demonstrated<br role="presentation" />that DXMS-Pal-SLNs effectively control acute infections without causing pulmonary infiltration or<br role="presentation" />excessive recruitment of immunocytes in lung tissues. These findings highlight the potential of neb-<br role="presentation" />ulized DXMS-Pal-SLNs as a promising therapeutic strategy for mitigating pneumonia-related in-<br role="presentation" />flammations.</p>

檔案與連結 (1)

url
https://doi.org/10.3390/pharmaceutics16070878檢視
已出版(紀錄版本) 開放

相關連結

指標

1 檢視次數

詳細資料

Logo image